Exploring Novel Therapeutics for Pulmonary Arterial Hypertension

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Molecular Biology

Background:

• Pulmonary arterial hypertension (PAH) involves progressive pulmonary artery narrowing.
• Bone morphogenetic protein (BMP) pathway dysregulation is key in PAH development.
• Current vasodilators improve prognosis but some patients remain refractory.

Purpose of the Study:

• To review recent advances in basic research for novel PAH treatments.
• To discuss the potential clinical applications of emerging PAH therapies.
• To highlight new strategies targeting molecular mechanisms of PAH.

Main Methods:

• Review of recent scientific literature on PAH pathogenesis and treatment.
• Analysis of emerging therapeutic targets and their mechanisms of action.
• Discussion of clinical trial data and future directions for PAH therapy.

Main Results:

• Sotatercept, an activin signaling inhibitor, is approved for PAH, restoring BMP pathway balance.
• Emerging strategies target PPAR-γ, inflammation, DNA damage, senescence, and growth factor receptors.
• These novel approaches aim to address unmet needs in PAH treatment.

Conclusions:

• Significant progress in understanding PAH molecular mechanisms is paving the way for new treatments.
• Targeting pathways like activin signaling and others offers promise for refractory PAH patients.
• Continued research is crucial for developing more effective and potentially curative therapies for PAH.